Korro Bio, Inc. reported its financial results for the third quarter of 2025, revealing a collaboration revenue of $1.1 million for the quarter and $5.1 million for the nine months ended September 30, 2025, a significant increase from no revenue in the same periods of 2024. The company, which focuses on RNA editing technologies for genetic medicine, has not yet generated revenue from product sales and continues to incur substantial operating losses, reporting a net loss of $18.1 million for the third quarter and $67.2 million for the nine months, compared to losses of $21.0 million and $62.4 million, respectively, in the prior year.
Operating expenses for the third quarter decreased to $20.3 million from $23.3 million in the same quarter of 2024, primarily due to reduced research and development costs, which fell to $13.8 million from $16.0 million. The decrease in R&D expenses was attributed to lower external costs associated with the KRRO-110 program, partially offset by increased clinical trial expenses. General and administrative expenses also declined slightly to $6.5 million from $7.3 million, mainly due to reduced professional services costs.
Korro Bio has undergone significant organizational changes, including a strategic workforce reduction of 19% in May 2025 and a further reduction of approximately 34% announced in November 2025. These moves are part of a broader strategy to streamline operations and extend the company's cash runway, which stood at $102.5 million as of September 30, 2025. The company anticipates that this capital will support its operations into the second half of 2027, although it acknowledges the need for additional funding to continue its research and development efforts.
The company is advancing its clinical programs, including the KRRO-110 trial for Alpha-1 Antitrypsin Deficiency (AATD) and the recently nominated KRRO-121 candidate targeting urea cycle disorders. However, the collaboration with Novo Nordisk has been paused for 12 months, which may impact future revenue recognition. Korro Bio's management remains focused on navigating the challenges of clinical development and regulatory approval while seeking to secure additional financing to support its ongoing operations and growth strategy.
About Korro Bio, Inc.
Korro Bio is a clinical-stage biopharmaceutical company developing RNA editing therapies to treat rare and prevalent diseases. Using its proprietary OPERA platform, it designs oligonucleotides to recruit endogenous ADAR enzymes for precise, transient RNA modifications. Its focus includes gene repair, protein modulation, and addressing undruggable targets, with a pipeline targeting conditions like alpha-1 antitrypsin deficiency, leveraging established delivery methods and aiming for disease-modifying, safe, and scalable genetic medicines.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.